Latest updates

2017 has been a very significant and productive year for BioGenCell. The company has expanded and thrived in many platforms conquering its predetermined goals and more.
A review of BioGenCell’s accomplishments for 2017:

  • BioGenCell has completed the 6 Months follow-up in its first in human, phase I/II clinical trial in CLI patients ( Identifier: NCT02805023). Results of this cohort of patients show that the treatment is safe and has therapeutic effects in both objective outcomes, including limb salvage, leg blood flow and wound healing as well as subjective outcomes including walking ability, reduction of pain and improved quality of life.
    This study is being conducted at the Laniado Hospital, headed by Dr. Mark J Niven, a worldwide leader in the field of diabetes and the Director of the Endocrine and Diabetes Unit, incorporating the Bildirici Center for Diabetes Care and Research. This disease is the most serious form of peripheral vascular disease (PVD) and is the direct cause of limb amputations, as well as significant patient morbidity and mortality.
    The goal beyond elimination of amputations is to extend lifespan and improve functionality and quality of life in our patients.
    BioGenCell looks forward to further testing its technology in a double blind randomized clinical trial (RTC) in the coming year and to conclusively prove the concept behind this technology.
  • BioGenCell has welcomed aboard Prof. Aaron Ciechanover , the Nobel Prize Laureate (2004, chemistry). Prof. Ciechanover has joined BioGenCell’s Scientific Advisory Board and is renowned for his groundbreaking discoveries on the ubiquitin system and its major roles in homeostasis and in pathogenetic mechanisms of many diseases that have paved the way to new platforms for drug development.
  • BioGenCell has won an EU competitive grant this year of over one million Euros. This prestigious DGO6 grant was granted by the Belgium Authorities in the Wallonia region of Belgium and will allow us to embark upon the company’s product development.
  • BioGenCell has opened a fully owned subsidiary in Belgium. The new company BioGenCell EU will continue in parallel with BioGenCell IL to advance its clinical studies, expansion of production and business development.
  • BioGenCell has welcomed aboard Mr. Marc Dechamps to its BioGenCell EU team, who will spearhead the activities in Europe. Formerly, Mr. Dechamps was the Executive Director of Specialty Care & Vaccines department at GSK, and subsequently, Head of the European Mid-Size Countries Region at ViiV Healthcare, a spinout company created by GSK and Pfizer.
  • BioGenCell has received the approval of both the Israeli Ministry of Health(MOH) and the Belgium Ministry of Health (FAMHP-Federal Agency for Medicines and Health Products) to continue its clinical trials on a larger scale as a double-blind placebo-controlled study.
  • BioGenCell has joint forces with Newcastle University Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute and with the Laniado diabetes center in Israel for research on a new regenerative medicine. All parties have embarked on a collaborative venture, bringing together different cell therapies that are currently pioneered in both countries towards a simple and persuasive new combination therapeutic of donor-derived pancreatic islets and patient’s own endothelial progenitor cells.
  • BioGenCell presented its innovative technology and insight to its clinical trial at the annual, renowned conference, The 8th World Congress and Exposition on Cell & Stem Cell Research, March 20-22, 2017 Orlando, Florida, USA The conference focused on exploring and exploiting novel techniques in Cellular and Stem Cell Research.
  • BioGenCell’s clinical study PI, Dr. Mark Niven, a worldwide leader in the field of diabetes and the Director of the Endocrine and Diabetes Unit, incorporating the Bildirici Center for Diabetes Care and Research at Laniado Hospital, Israel, gave a scientific presentation of the company’s preliminary results at the 53rd annual meeting of the European Association for the Study of Diabetes, EASD held on the 11-15 of September in Lisbon, Portugal. The conference program can be seen on
  • BioGenCell presented its promising results from its First In Human (FIH) study in “no option’ CLI patients at the 45th Annual VEITH symposium on Vascular and Endovascular Issues, organized by the world renowned Prof. Veith who is also on BioGenCell’s scientific advisory board. ( ). BioGenCell’s scientific advisor, Dr. Michael Frogel, an Associate Professor of Pediatrics at the Albert Einstein College of Medicine, Principal Investigator for the New York City Pediatric Disaster Coalition (PDC) and Medical Director of the Pediatric Disaster Mental Health Initiative at Maimonides Medical Center, NY, USA, gave the presentation in November to an audience of prominent vascular surgeons, interventional radiologists and interventional cardiologists interested in hearing more on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques in medical fields.
  • BioGenCell presented the preliminary results of its clinical trial at the Global Investor Forum Maastricht, the Netherlands 8-9 Feb 2017 – an opportunity for Israeli startups in RegMed and MedTech. The Global Investor Forum exposes promising biomed Start-Ups and joins the powerful global BIOMED network of the world’s leading investors, entrepreneurs, corporates and key physicians. The focus was on Regenerative Medicine and Medical Devices.
  • BioGenCell took part in the annual Israeli Entrepreneur Week (Yazamut On the Bar) where high-tech and biotech companies are encouraged to speak to a young audience in bars or pubs and tell their story. Dr. Yael Porat, BioGenCell’s founder and CEO, told her personal story to a full house in a Tel-Aviv bar inspiring both young and old to never give up on their dreams in her lecture “Behind the Scenes of Tomorrow’s Medicine- Your Own Blood is Your Best Medicine Cabinet.”
  • BioGenCell and its colleagues wrote a full chapter for a peer reviewed textbook which describes among things the method and rational behind its clinical trial. The Scientific publication of the chapter ‘Cell Therapy for Vascular Diseases in Israel’ appears in the textbook ”Vascular Surgery, A Global Perspective”, edited by Alan Dardik.